% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • kingedxxxxx kingedxxxxx Aug 6, 2014 11:03 AM Flag

    Positive view on current share price

    Here is a completely different perspective of Mannkind's share price. If you look back at the charts for the past two years, you will notice that last year the stock was valued at around $6 per share. The year before it was only valued at about $2 per share. Now that we have FDA approval, it looks like the stock is settling here at around $8 per share. But wait a minute.

    The stock was valued at $6 per share for a long time. This was before FDA approval, any partnership deal, or any revenues with a company that burns through quite a bit of cash quarter after quarter. So, what will the market value MannKind after partnership? What will market value Technosphere and potential revenues from licensing fees and more? What will market value MannKind once revenues start taking form?

    Considering that MannKind held $6 area for such a long time without FDA approval or any of the other significant milestones yet to come, one has to wonder if $8 is a fair valuation. Going back to $6 would not even make sense. I would have to argue that $8 is not gong to be where this thing settles as the market waits for sales results. Likely, a $4b market cap ($10+ per share) or higher may be a more realistic area once the partnership deal is finalized and the market can anticipate revenues.

    One last thing. I believe that doctor's will be slow to prescribe Afrezza. However, I believe that once they receive positive feedback from first few patients, sales will increase rapidly. I also believe many underestimate the demand from the actual diabetic industry. Word will get out and patients will demand to be prescribed Afrezza.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.62+0.02(+3.63%)Sep 30 4:00 PMEDT